ArticlePloS one2015
The Macrophage Galactose-Type C-Type Lectin (MGL) Modulates Regulatory T Cell Functions.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Ribociclib-Induced Vitiligo: A Case Report with Histological, Dermatoscopic, Confocal Microscopy, and LC-OCT Findings Along with a Narrative Literature Review.Dermatology practical & conceptual · 2026Review
- Bioinformatic Analysis of C1GALT1 in Cancer: Insights Into Prognosis, Metastasis and Therapeutic Potential.Cancer reports (Hoboken, N.J.) · 2025Article
- MGL/CLEC10A is an important C-type lectin receptor activated in the innate immune response toFrontiers in immunology · 2025Article
- Mannose and Lactobionic Acid in Nasal Vaccination: Enhancing Antigen Delivery via C-Type Lectin Receptors.Pharmaceutics · 2024Review
- Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma.International journal of molecular sciences · 2022Review
- Immune effects of CDK4/6 inhibitors in patients with HREBioMedicine · 2022Article
- Glycoproteins Presenting Galactose andInternational journal of molecular sciences · 2021Article
- Article
- Enhanced Immune Response Against the Thomsen-Friedenreich Tumor Antigen Using a Bivalent Entirely Carbohydrate Conjugate.Molecules (Basel, Switzerland) · 2020Article
- Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.Seminars in immunology · 2020Review
- Immature O-glycans recognized by the macrophage glycoreceptor CLEC10A (MGL) are induced by 4-hydroxy-tamoxifen, oxidative stress and DNA-damage in breast cancer cells.Cell communication and signaling : CCS · 2019Article
- A novel polysaccharide fromRSC advances · 2018Article
- GalNAc-Specific Soybean Lectin Inhibits HIV Infection of Macrophages through Induction of Antiviral Factors.Journal of virology · 2018Article
- Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.Frontiers in immunology · 2018Article
- Region-Resolved Quantitative Proteome Profiling Reveals Molecular Dynamics Associated With Chronic Pain in the PNS and Spinal Cord.Frontiers in molecular neuroscience · 2018Article
- MGL Receptor and Immunity: When the Ligand Can Make the Difference.Journal of immunology research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T cells (Tregs) are physiologically designed to prevent autoimmune disease and maintain self-tolerance. In tumour microenvironments, their presence is related to a poor prognosis, and they influence the therapeutic outcome due to their capacity to suppress the immune response by cell-cell contact and to release immunosuppressive cytokines. In this study, we demonstrate that Treg immunosuppressive activity can be modulated by the cross-linking between the CD45RA expressed by Tregs and the C-type lectin MGL. This specific interaction strongly decreases the immunosuppressive activity of Tregs, restoring the proliferative capacity of co-cultured T lymphocytes. This effect can be attributed to changes in CD45RA and TCR signalling through the inhibition of Lck and inactivation of Zap-70, an increase in the Foxp3 methylation status and, ultimately, the reduced production of suppressive cytokines. These results indicate a role of MGL as an immunomodulator within the tumour microenvironment interfering with Treg functions, suggesting its possible use in the design of anticancer vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.